MARLBOROUGH, Mass.--(BUSINESS WIRE)--EXACT Sciences Corporation (NASDAQ: EXAS) today announced the publication in the American Journal of Gastroenterology the results of a multi-center study of EXACT’s Version 2 technology for stool-based DNA screening for colorectal cancer. The Company previously disclosed this study’s acceptance for publication and its top line performance for colorectal cancer detection. The study, conducted by Steven H. Itzkowitz, M.D, Professor of Medicine, Mount Sinai School of Medicine and his collaborators involved samples from 445 patients, which consisted of 82 colorectal cancers and 363 normal controls. The vast majority of cancers (83%) were detected regardless of tumor stage, tumor location, patient age, or the presence or absence of symptoms, with a specificity of 82%. In addition, 86% (6 of 7) precancerous adenomas with high grade dysplasia were also detected.
